stemmacolore
Search

Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

Studio prospettico multicentrico italiano non interventistico su abemaciclib come terapia adiuvante in combinazione con il trattamento endocrino nel carcinoma mammario precoce, linfonodo positivo, ad alto rischio di recidiva (IT – PATH)

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
2023-13057
Codice EudraCT
NP
Sponsor/Promotore
Eli Lilly and Company
Tipologia
Osservazionale
Fase
.
Unità Operativa
Oncologia 2
Principal Investigator

Studio di fase 3, randomizzato, in aperto su sacituzumab govitecan rispetto al trattamento scelto dal medico in partecipanti affette da cancro endometriale che hanno ricevuto una precedente chemioterapia a base di platino e immunoterapia anti-PD-1/PD-L1

Stato
Autorizzato - In attesa di apertura
Codice studio
GS-US-682-6769 (ASCENT-GYN-01)
Codice EudraCT
2024-511957-23
Sponsor/Promotore
Gilead Sciences, Inc
Tipologia
Sperimentale
Fase
III
Unità Operativa
Oncologia 2
Principal Investigator

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
JZP598-303 (EmpowHER 303)
Codice EudraCT
2023-508960-31-00
Sponsor/Promotore
Jazz Pharmaceuticals Ireland Limited
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator

Studio di fase 2, multicentrico, randomizzato, in aperto sull’inibitore di ATR tuvusertib in combinazione con l’inibitore di PARP niraparib o l’inibitore di ATM lartesertib in partecipanti con cancro ovarico epiteliale con mutazioni di BRCA e/o positività al deficit di ricombinazione omologa (HRD) che è progredito durante una precedente terapia con inibitori di PARP.

Stato
Autorizzato - In attesa di apertura
Codice studio
MS201924_0002 (DDRiver EOC 302)
Codice EudraCT
2024-511202-23-00
Sponsor/Promotore
Merck KGaA
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator

Studio DESTINY Breast Respond HER2-low Europe: Studio prospettico, non interventistico (NIS) su trastuzumab deruxtecan in pazienti con carcinoma mammario non resecabile e/o metastatico a bassa espressione di HER2 unitamente ad un registro di malattia per pazienti trattati con chemioterapia convenzionale

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
DS8201-0005-NIS-MA
Codice EudraCT
NP
Sponsor/Promotore
DAIICHI SANKIO DEVELOPMENT LIMITED
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Studio osservazionale retrospettivo-prospettico sull’influenza del ritmo circadiano e della tempistica delle infusioni sull’efficacia dei trattamenti basati sull’immunoterapia per i tumori solidi: lo studio CIRCE

Stato
Aperto - reclutamento in corso
Codice studio
IOV-2024-CIRCE
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top